# Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

Study · id `cardio:ct-nct04419467` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04419467](<https://clinicaltrials.gov/study/NCT04419467>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04419467

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

## Technical summary

Registry record NCT04419467. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-14 (actual); primary completion 2022-10-24 (actual). Results posted on 2023-12-06.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 114 participants (enrolled count; ClinicalTrials.gov record NCT04419467, source copy `cardio:ctgov-nct04419467-2023-12-06`, retrieved 2026-10-26)
- Started: 2020-09-14 (actual) (ClinicalTrials.gov record NCT04419467, source copy `cardio:ctgov-nct04419467-2023-12-06`, retrieved 2026-10-26)
- Primary completion: 2022-10-24 (actual) (ClinicalTrials.gov record NCT04419467, source copy `cardio:ctgov-nct04419467-2023-12-06`, retrieved 2026-10-26)
- Completion: 2022-10-24 (actual) (ClinicalTrials.gov record NCT04419467, source copy `cardio:ctgov-nct04419467-2023-12-06`, retrieved 2026-10-26)
- Results first posted: 2023-12-06 (ClinicalTrials.gov record NCT04419467, source copy `cardio:ctgov-nct04419467-2023-12-06`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Israel; New Zealand; Puerto Rico (ClinicalTrials.gov record NCT04419467, source copy `cardio:ctgov-nct04419467-2023-12-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04419467-2023-12-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
- Condition: Diabetic Kidney Disease (DKD)
- Intervention (Biological): CSL346
- Intervention (Drug): Placebo
- Lead sponsor: CSL Behring
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: CSL Behring (`cardio:org-csl-behring`)

## Provenance

Content hash: e000ed3e0ffb5bfee98867b22c6082ba811f8ab635a671f8c33df10137cc12f7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
